During the "14th Five-Year Plan" period, Jingjing Pharmaceutical Plan proposed a "two-wheel drive" development strategy
focusing on the "Five Golden Flower" traditional Chinese medicine main business, supplemented by characteristic chemical APIs and chemical preparations.
It is reported that focusing on the traditional Chinese medicine business, Jingjing Pharmaceutical recently continued to sell the equity of Kingsley Pharmaceutical and abandoned the biomedical business
.
On December 1, Jingjing Pharmaceutical announced that the company intends to sign the "State-owned Property Rights Transfer Contract" with Yixing Environmental Science Park Equity Investment Partnership (Limited Partnership) to sell its 3.
85% equity interest in Jiangsu Jinsili Pharmaceutical Co.
, Ltd.
, a holding subsidiary, through a large transaction method through the national small and medium-sized enterprise share transfer system, with a transaction amount of 10 million yuan
.
It is reported that this is not the first time that Jinghua Pharmaceutical has sold the equity of
Kingsley Pharmaceutical.
On September 30, Jingjing Pharmaceutical issued an announcement that the company intends to transfer 26.
93% of the equity of Kingsley Pharmaceutical to Jiangsu Jianzhong Biopharmaceutical Co.
, Ltd.
at a transaction price of 70 million yuan
.
"Biomedicine is no longer the focus of the company's development, and the elimination of non-performing industries with weak correlation and low yield, and the realization of the main business focus of listed companies and slimming and fitness are important links
in the company's current development strategy.
" Jinghua Pharmaceutical believes that the investment in Kingsley Pharmaceutical has not achieved the company's investment purpose, and the results of achieving industrial synergy with Jinghua Pharmaceutical in its main business areas such as drug production, health product production, drug circulation, and medical care and health care are relatively limited
.
The data shows that in 2020, 2021 and the first half of 2022, Kingsley Pharmaceutical achieved a loss of 12.
1775 million yuan, a loss of 7.
585 million yuan and a loss of 2.
6031 million yuan
respectively attributable to the shareholders of the parent company.
Jingjing Pharmaceutical pointed out that during the "14th Five-Year Plan" period, the company planned to put forward a "two-wheel drive" development strategy focusing on the main business of "five golden flowers" traditional Chinese medicine, supplemented by characteristic chemical APIs and chemical preparations, and continuously improving competitiveness
.
It is understood that the company's main products Wang's Baochi Pill, Zhengchai Hujiu Granules, Ji Desheng Snake Tablets, Golden Buckwheat Chips, Da Chai Hu Granules and other "five golden flowers" are the treasure house of traditional medicine of the motherland, and have deep influence and good reputation
in Jiangsu and surrounding East China.
Among the company's proprietary Chinese medicine products, Wang's Baochi Pill and Ji Desheng Snake Pill are exclusive varieties, and they have been listed as national traditional Chinese medicine secret varieties; Zhengchai Huying granules only hold production approvals with the experimental pharmaceutical factory of the Chinese Academy of Chinese Medical
Sciences.
As a characteristic drug type in China, traditional Chinese medicine has been supported by national policies, and its performance growth is certain
.
With the aggravation of the aging population, the base of patients with chronic diseases continues to expand, and the rigid demand for traditional Chinese medicine will continue to grow
.
Some institutions said that today's policies continue to promote the coordinated development of Chinese and Western medicine, creating a better growth environment
for the Chinese medicine industry.
The inclusion of proprietary Chinese medicines and other products in the scope of centralized procurement is expected to promote the entry of traditional Chinese medicine into hospitals and broaden the channels
for increasing volume.
"We are optimistic about the subsequent expansion of the market space of the traditional Chinese medicine sector, and the performance growth of companies in the traditional Chinese medicine sector will be sustainable
in the future.
"
In addition, some people said that the state has issued a number of policies to encourage the comprehensive development of traditional Chinese medicine, encourage traditional Chinese medicine innovation and talent development, and other traditional Chinese medicine policies have been intensively introduced, which fully shows that China attaches great importance
to the development of traditional Chinese medicine.
According to data from relevant departments, the overall size of China's traditional Chinese medicine market in 2021 has exceeded 800 billion yuan
.
With the continuous release of national policy dividends, it is expected that the industry will maintain double-digit growth in the future, and the overall size of the traditional Chinese medicine market can exceed 1 trillion yuan
.
Jingjing Pharmaceutical will focus on the traditional Chinese medicine industry by eliminating non-performing industries with low correlation and low yield, or will achieve new development opportunities
.
Data show that in the first three quarters of 2022, Jinghua Pharmaceutical achieved operating income of 1.
175 billion yuan, a year-on-year increase of 21.
26%; the net profit attributable to the parent was 169 million yuan, a year-on-year increase of 31.
52%; The net profit of non-attributable parent was 156 million yuan, a year-on-year increase of 67.
38%.
In Q3 alone, the company achieved revenue of 383 million yuan, +17.
08% year-on-year), net profit attributable to parents of 39 million yuan (year-on-year +71.
48%), and net profit attributable to non-owners of 36 million yuan (+457.
91% year-on-year).
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
![3-bromodibenzo[b,d]thiophene](https://file.echemi.com/fileManage/upload/cas/822/bb4496d0-decc-11eb-89d6-0255ac100033.png)
